Ibrahim Ali Al Bataj

Dr. Ibrahim Ali Al Bataj

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2024 in Life
Verified
Journal Article
Open access
PDF file
AEAhmed M E Elkhalifa
Ahmed M E Elkhalifa
MNMehak Nazar
Mehak Nazar
SASofi Imtiyaz Ali
Sofi Imtiyaz Ali
IKIbraq Khursheed
Ibraq Khursheed
STSyed Taifa
Syed Taifa
SNShowkat Ul Nabi
Showkat Ul Nabi
Diabetes mellitus (DM) is characterized by an absolute decline in insulin secretion and peripheral resistance and is the most prevalent metabolic and endocrine disorder. However, the pathogenesis of DM also includes adipocyte insulin resistance, increased glucagon secretion, increased renal glomerular glucose absorption, and neurotransmitter dysfunction. Although there is a wide spectrum of therapeutics available for glycemic control, owing to the identification of various pathogenic determinants of DM, management of DM remains challenging and complex. Current therapeutic interventions against DM focus mostly on glycemic control without considering the other pathological determinants that eventually lead to treatment failure and the progression of DM. Furthermore, long-term use of these conventionally available anti-diabetic drugs leads to various side effects, henceforth development of novel drugs against DM remains an unending search strategy for researchers. Various studies conducted in various parts of the world have proposed that these novel therapeutic interventions target multiple and alternate pathogenic hotspots involved in DM. The current review article discusses novel therapeutic options that hold particular promise to support their safety and discuss the side effects resulting from their use so that these novel candidate drugs can be effectively fabricated into potential drugs for the treatment of DM.

1 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
AEAhmed M E Elkhalifa
Ahmed M E Elkhalifa
AEAbozer Elderdery
Abozer Elderdery
IBIbrahim Ali Al Bataj
Ibrahim Ali Al Bataj
ATAbdelhakam G. Tamomh
Abdelhakam G. Tamomh
MAMasaud M. Alyami
Masaud M. Alyami
PMPooi Ling Mok
Pooi Ling Mok
COVID‐19 is a global pandemic viral infection that has affected millions worldwide. Limited data is available on the effect of COVID‐19 on hematological parameters in Saudi Arabia. This study is aimed at examining the role of hematological parameters among COVID‐19 patients admitted to King Khalid Hospital in Najran, Saudi Arabia. This is a retrospective, hospital‐based study of 514 cases who were recruited during August to October 2020. 257 COVID‐19 patients formed the study group, and a further 257 negative subjects formed the control group. Anemia was significantly elevated in positive subjects over controls (respectively, 64.2% and 35.8%), with patients 2.5 times more likely to be anemic (p < 0.01). Thrombocytopenia was higher in patients over controls (respectively, 62% and 38%), with patients ~1.7 times more likely to be thrombocytopenic (p < 0.01). Moreover, leukopenia was significantly higher in patients over controls (respectively, 71% and 29%), with positive subjects ~2.6 times more likely to be leukopenic. Our study results indicate that mild anemia associated with leukopenia may have diagnostic value for COVID‐19. Careful assessment of hematological parameters, at baseline and throughout the disease path, will assist physicians in formulating personalized approaches to treatment and promptly offer intensive care to those in greater need.